Speakers
Andrew Pierce
Vice President - Translational Biology
Crescendo Biologics
Day One
Wednesday, January 26 2022
2:00 pm | Primary Pharmacology of CB213, a LAG-3-PD1 Co-targeting Humabody™
Day Two
Thursday, January 27 2022
9:30 am | Panel Discussion: Tug of War: Understanding How LAG-3 & PD-1 Interplay with One Another
Creg Workman
Research Assistant
University of Pittsburgh
Day Two
Thursday, January 27 2022
12:15 pm | How does LAG-3 mediate its inhibitory function?
Ella Ioffe
Director
Regeneron Pharmaceuticals
Day One
Wednesday, January 26 2022
1:30 pm | Targeting LAG-3 in Cancer Immunotherapy: Advancing Beyond PD-1 Blockade
Day Two
Thursday, January 27 2022
2:15 pm | Panel Discussion: Compare Bispecific & Combination Therapeutic Approaches
Frederic Triebel
Chief Scientific Officer & Chief Medical Officer
Immutep
Day One
Wednesday, January 26 2022
12:00 pm | My Journey Through the LAG-3/MHC Class II Landscape: 1988-2021
Giuseppe Gullo
Clinical Lead
Regeneron Pharmaceuticals
Day Two
Thursday, January 27 2022
10:15 am | Bridging Preclinical & Clinical Worlds
Jessica Chacon
Assistant Professor
Texas Tech University Health Sciences Center
Day Two
Thursday, January 27 2022
9:30 am | Panel Discussion: Tug of War: Understanding How LAG-3 & PD-1 Interplay with One Another
Jon Piganelli
Associate Professor School of Medicine
University of Pittsburgh
Laura Codari Deak
Team & Research Project Leader, Principal Scientist
Roche Innovation Center
Day One
Wednesday, January 26 2022
9:30 am | A Novel Bispecific Checkpoint Inhibitor Antibody to Preferentially Block PD-1 & LAG-3 on TILs Whilst Sparing Treg Activation
Laurel Mckee
Scientist & Senior Associate - Research
L Hoffman La Roche
Day One
Wednesday, January 26 2022
2:30 pm | Roche CDx is now Personalised Healthcare Solutions
Marc Voigt
Chief Executive Officer
Immutep
Day One
Wednesday, January 26 2022
9:00 am | Opening Remarks: Reviewing the Past 12 Months of LAG-3 Therapeutic Development
Maurizio Pellecchia
Professor of Biomedical Sciences Daniel Hays Endowed Chair in Cancer Research Director, Center for Molecular and Translational Medicine
UCR School of Medicine
Michelle Morrow
VP, Preclinical Translational Pharmacology
F-Star Biotechnology
Day One
Wednesday, January 26 2022
11:00 am | Rescuing Checkpoint Inhibitor FS118
Paul Moore
Vice President - Immunology & Cell Biology
MacroGenics
Day One
Wednesday, January 26 2022
11:30 am | Advancing Tebotelimab, a Bispecific PD-1 x LAG-3 DART Molecule, From Concept to Clinical Assessment
Day Two
Thursday, January 27 2022
9:30 am | Panel Discussion: Tug of War: Understanding How LAG-3 & PD-1 Interplay with One Another
Richard Wu
Professor
Ohio State University
Day Two
Thursday, January 27 2022
2:15 pm | Panel Discussion: Compare Bispecific & Combination Therapeutic Approaches
Sarah Lauder
Research Associate
Cardiff University
Day Two
Thursday, January 27 2022
12:45 pm | Sequential Targeting of PI3Kd & LAG-3 as an Effective Anti- Cancer Approach
Segundo Gonzalez
Leader
Universidad de Oviedo
Day Two
Thursday, January 27 2022
9:00 am | LAG-3 Blockade with Relatlimab Restores Anti Leukemic Immune Response in Chronic Lymphocytic Leukemia
Shuqi Zeng
Senior Director
Medical Epimab Biotherapeutics
Day One
Wednesday, January 26 2022
3:25 pm | Phase I Dose Escalation Experience Of EMB-02 (a PD-1/ LAG-3 bsAb) In Multiple Countries (US, China & Others) Simultaneously
Xiaobo Mao
Associate Professor
Johns Hopkins School of Medicine
Day Two
Thursday, January 27 2022
2:45 pm | The role of LAG-3 in Mediating Alpha-Synuclein Pathology in Parkinson’s Disease
Yvonne Saenger
Director of Melanoma Immunotherapy
Columbia University
Day Two
Thursday, January 27 2022